Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 510 across all filing types
Latest filing 2022-07-07 Capital/Financing Update
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Spełnienie warunków wypłaty drugiej transzy finansowania z EBI - Content (PL)
Capital/Financing Update Classification · 1% confidence The document text, written in Polish, discusses the receipt of information from the European Investment Bank (EBI) regarding the fulfillment of conditions for the disbursement of the second tranche of financing (EUR 3 million out of EUR 10 million total). It also mentions the associated warrant subscription rights that EBI gains upon this payment. This clearly relates to the company securing funds, changing its capital structure, or receiving financing. Based on the definitions, this falls under 'Capital/Financing Update' (CAP). The document is a direct announcement of a financing event, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains substantive details about the funding received and its implications.
2022-07-07 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na ZWZ 30.06.2022
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text is a list detailing shareholders who held at least 5% of the voting rights at the Annual General Meeting (Zwyczajne Walne Zgromadzenie) held on June 30, 2022. This directly relates to the results of a shareholder vote at a general meeting. The most appropriate category is Declaration of Voting Results & Voting Rights Announcements (DVA). The document is short and contains the actual results/list, not an announcement about the results being published.
2022-07-01 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Walnym Zgromadzeniu Spółki, które odbyło się w dniu 30 czerwca 2022 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text is very short (203 characters) and states that the Management Board of Scope Fluidics S.A. is enclosing a list of shareholders who held at least 5% of the votes at the Annual General Meeting (Zwyczajnym Walnym Zgromadzeniu) held on June 30, 2022. This content relates directly to the results or participants of a shareholder meeting. The most specific category for voting results is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it is a list of attendees/major holders related to the AGM, DVA covers official results from shareholder votes. Since the document is an announcement enclosing a list related to the AGM voting structure, DVA is the best fit over AGM-R (which is for presentations/materials) or RNS (which is a fallback). Given the brevity and the nature of enclosing specific data related to a meeting's outcome/structure, DVA is appropriate.
2022-07-01 Polish
Rozpoczęcie realizacji działań w zakresie dystrybucji systemu PCR|ONE - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is a formal announcement from the Management Board of Scope Fluidics S.A. regarding the commencement of activities related to the distribution of the PCR|ONE system under an Early Access Program (PEA). It details operational plans, collaboration with a distributor (Bioanalytic sp. z o.o.), and the objectives of the program, such as gathering feedback and verifying sales potential. This content describes a specific business development, operational update, or strategic move, rather than a standard financial report (10-K, IR, ER) or a formal regulatory filing like a director's dealing or capital change. Since it is a detailed update on business operations and strategy execution, it fits best under Management Reports (MDA), which covers management's explanation of business trends and outlook, or potentially Regulatory Filings (RNS) if it were less specific. Given the detailed nature of the operational update, MDA is the most appropriate fit, as it is an explanation of current business activities.
2022-06-27 Polish
Informacja na temat działań podjętych w związku ze zmianą przepisów dotyczących deklaracji zgodności wyrobów do diagnostyki in-vitro z przepisami Unii Europejskiej - Content (PL)
Regulatory Filings Classification · 1% confidence The document is written in Polish and discusses regulatory compliance changes concerning CE marking for medical devices (specifically IVDD transitioning to IVDR) affecting the company's subsidiaries (Curiosity Diagnostics and Bacteromic). It details actions taken regarding product certification (panels and analyzers) before and after the May 26, 2022 deadline. This type of communication, focusing on regulatory compliance status, legal requirements, and potential future reporting based on regulatory decisions (like those from Prezes URPL), fits best under 'Legal Proceedings Report' (LTR) if it relates to regulatory actions or 'Regulatory Filings' (RNS) as a general regulatory update. Since it specifically addresses compliance with EU directives and potential future reporting on regulatory decisions, it is a specific regulatory announcement. Given the options, 'LTR' covers significant legal/regulatory matters, and 'RNS' is the general regulatory fallback. Because it is a direct announcement about navigating regulatory changes and potential future reporting on regulatory outcomes, 'RNS' (Regulatory Filings) is the most appropriate general category for this type of mandatory disclosure that isn't a standard financial report or management change.
2022-05-26 Polish
Wyniki walidacji systemu BacterOMIC z rozszerzonym panelem diagnostycznym - Content (PL)
Regulatory Filings Classification · 1% confidence The document is written in Polish and discusses the validation and subsequent regulatory filing (submission to Prezes URPL) of an expanded diagnostic panel (BacterOMIC) by a subsidiary (Bacteromic). It details technical validation results (sensitivity, specificity) related to antibiotic resistance testing and mentions compliance with EU directives (CE-IVD, IVDR). This content describes a significant operational or product development milestone that impacts the company's core business/technology, often released as a material event announcement. Since it is not a standard financial report (10-K, IR, ER) or a specific corporate action (DIV, SHA), and it details a significant operational/regulatory step, it fits best under a general Regulatory Filing (RNS) or potentially a Legal/Regulatory update if the focus was on the submission itself. Given the context of reporting a major technical validation and subsequent regulatory submission for market access, RNS (Regulatory Filings/General Regulatory Announcements) is the most appropriate general category for this type of material, non-standardized announcement.
2022-05-25 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.